- Home
- CVM vs SYBX Comparison
CVM vs SYBX Comparison
Compare CVM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- SYBX
- Stock Information
- Founded
- CVM 1983
- SYBX N/A
- Country
- CVM United States
- SYBX United States
- Employees
- CVM N/A
- SYBX N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- SYBX Health Care
- Exchange
- CVM Nasdaq
- SYBX Nasdaq
- Market Cap
- CVM 18.1M
- SYBX 16.4M
- IPO Year
- CVM 1987
- SYBX N/A
- Fundamental
- Price
- CVM $9.53
- SYBX $1.46
- Analyst Decision
- CVM
- SYBX
- Analyst Count
- CVM 0
- SYBX 0
- Target Price
- CVM N/A
- SYBX N/A
- AVG Volume (30 Days)
- CVM 386.2K
- SYBX 53.6K
- Earning Date
- CVM 08-14-2025
- SYBX 08-07-2025
- Dividend Yield
- CVM N/A
- SYBX N/A
- EPS Growth
- CVM N/A
- SYBX N/A
- EPS
- CVM N/A
- SYBX N/A
- Revenue
- CVM N/A
- SYBX N/A
- Revenue This Year
- CVM N/A
- SYBX N/A
- Revenue Next Year
- CVM N/A
- SYBX N/A
- P/E Ratio
- CVM N/A
- SYBX N/A
- Revenue Growth
- CVM N/A
- SYBX N/A
- 52 Week Low
- CVM $1.98
- SYBX $0.90
- 52 Week High
- CVM $39.30
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- CVM 65.33
- SYBX 52.54
- Support Level
- CVM $8.04
- SYBX $1.33
- Resistance Level
- CVM $9.42
- SYBX $1.67
- Average True Range (ATR)
- CVM 0.94
- SYBX 0.12
- MACD
- CVM -0.05
- SYBX -0.01
- Stochastic Oscillator
- CVM 90.37
- SYBX 38.24
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.